FDA Questions Validity of Smoking Cessation Drug Research FDA Questions Validity of Smoking Cessation Drug Research

The FDA has raised concerns about a postmarketing study that examined adverse neuropsychiatric events associated with smoking cessation drugs varenicline and bupropion.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Source Type: news